{"count":43797,"next":"https://cinder.proteo.info/api/ms_vocab/?format=json&limit=20&offset=24900&ordering=-accession","previous":"https://cinder.proteo.info/api/ms_vocab/?format=json&limit=20&offset=24860&ordering=-accession","results":[{"accession":"CLO:0018128","name":"ND06842 cell","definition":"[' POPULATION/CONVENIENCE CONTROL']","term_type":"cell line"},{"accession":"CLO:0018127","name":"ND06841 cell","definition":"[' ISCHEMIC STROKE']","term_type":"cell line"},{"accession":"CLO:0018126","name":"ND06852 cell","definition":"[\" PARKINSON'S DISEASE YOUNG ONSET PARKINSON'S DNA PANEL; AFFECTED INDIVIDUALS\"]","term_type":"cell line"},{"accession":"CLO:0018125","name":"ND06843 cell","definition":"[' ALS PANEL; GREATER THAN 7 YEARS SURVIVAL AMYOTROPHIC LATERAL SCLEROSIS ALS PANEL CAUCASIAN FROM THE UNITED STATES']","term_type":"cell line"},{"accession":"CLO:0018124","name":"ND06854 cell","definition":"[\" LATE ONSET PARKINSON'S DNA PANEL, AFFECTED INDIVIDUALS PARKINSON'S DISEASE\"]","term_type":"cell line"},{"accession":"CLO:0018123","name":"ND06853 cell","definition":"[\" PARKINSON'S DISEASE\"]","term_type":"cell line"},{"accession":"CLO:0018122","name":"ND06856 cell","definition":"[\" PARKINSON'S DISEASE YOUNG ONSET PARKINSON'S DNA PANEL; AFFECTED INDIVIDUALS\"]","term_type":"cell line"},{"accession":"CLO:0018121","name":"ND06855 cell","definition":"[\" POPULATION/CONVENIENCE CONTROL CONTROL PANEL FOR LATE ONSET PARKINSON'S; UNAFFECTED INDIVIDUALS\"]","term_type":"cell line"},{"accession":"CLO:0018120","name":"ND06858 cell","definition":"[\" LATE ONSET PARKINSON'S DNA PANEL, AFFECTED INDIVIDUALS PARKINSON'S DISEASE\"]","term_type":"cell line"},{"accession":"CLO:0018119","name":"ND06857 cell","definition":"[\" LATE ONSET PARKINSON'S DNA PANEL, AFFECTED INDIVIDUALS PARKINSON'S DISEASE\"]","term_type":"cell line"},{"accession":"CLO:0018118","name":"GM12567 cell","definition":"[' CEPH/FRENCH PEDIGREE 12']","term_type":"cell line"},{"accession":"CLO:0018117","name":"GM16953 cell","definition":"[' XERODERMA PIGMENTOSUM, COMPLEMENTATION GROUP D; XPD']","term_type":"cell line"},{"accession":"CLO:0018116","name":"GM12568 cell","definition":"[' CEPH/FRENCH PEDIGREE 12']","term_type":"cell line"},{"accession":"CLO:0018115","name":"GM16954 cell","definition":"[' XERODERMA PIGMENTOSUM, COMPLEMENTATION GROUP D; XPD']","term_type":"cell line"},{"accession":"CLO:0018114","name":"GM12571 cell","definition":"[' CEPH/FRENCH PEDIGREE 12']","term_type":"cell line"},{"accession":"CLO:0018113","name":"GM16925 cell","definition":"[' OSTEOGENESIS IMPERFECTA, TYPE IV; OI4 COLLAGEN, TYPE I, ALPHA-2; COL1A2']","term_type":"cell line"},{"accession":"CLO:0018112","name":"GM16950 cell","definition":"[' XERODERMA PIGMENTOSUM, COMPLEMENTATION GROUP D; XPD']","term_type":"cell line"},{"accession":"CLO:0018111","name":"GM12572 cell","definition":"[' CEPH/FRENCH PEDIGREE 12']","term_type":"cell line"},{"accession":"CLO:0018110","name":"GM16951 cell","definition":"[' XERODERMA PIGMENTOSUM, COMPLEMENTATION GROUP D; XPD']","term_type":"cell line"},{"accession":"CLO:0018109","name":"GM12569 cell","definition":"[' CEPH/FRENCH PEDIGREE 12']","term_type":"cell line"}]}